载药白蛋白纳米粒的研究进展

doi:10.19803/j.1672-8629.2020.09.19

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (9): 636-642.
DOI: 10.19803/j.1672-8629.2020.09.19

载药白蛋白纳米粒的研究进展

李辉¹, 王丹丹¹, 杨菡², 张学农^1,*

¹苏州大学药学院,江苏苏州 215123;
²江苏海岸药业有限公司,江苏苏州 215228

收稿日期:2020-08-17 修回日期:2020-08-17 出版日期:2020-09-15 发布日期:2020-08-17
通讯作者: ^*张学农,男,教授·博导,药物新技术与新剂型。E-mail:zhangxuenong@163.com
作者简介:李辉,男,硕士,靶向药物递送。
基金资助:
国家自然科学基金(81773183);江苏省优势学科资助(PAPD);江苏省研究生科研创新计划(KYCX19_1973)

Research Progress on Drug-loaded Albumin Nanoparticles

LI Hui¹, WANG Dandan¹, YANG Han², ZHANG Xuenong^1,*

¹College of Pharmaceutical sciences, Suzhou University, Suzhou Jiangsu 215123, China;
²Jiangsu Hai'an Pharmaceutical Co. , Ltd, Suzhou Jiangsu 215228, China

Received:2020-08-17 Revised:2020-08-17 Online:2020-09-15 Published:2020-08-17

摘要/Abstract

摘要： 白蛋白具有良好生物相容性、无毒、无免疫原性等特点,其在新型给药载体方面的应用不断增加。尤其是对于肿瘤治疗,白蛋白纳米粒表现出一些独特的优势。通过分析近期国内外的文章,对白蛋白智能纳米粒在肿瘤靶向、肿瘤组织渗透、刺激敏感型上的应用及其制备工艺进行了综述。

关键词: 白蛋白, 纳米粒, 肿瘤, 靶向性, 载药

Abstract: Albumin is widely used due to its good biocompatibility, nontoxicity and non-immunogenicity. Albumin nanoparticles have shown unique advantages in oncotherapy. This article summarizes the applications of albumin nanoparticles in tumor treatment and their preparation methods based on articles recently published at home and abroad.

Key words: albumin, nanoparticle, tumor, targeting, drug-loaded

中图分类号:

R979.1

李辉, 王丹丹, 杨菡, 张学农. 载药白蛋白纳米粒的研究进展[J]. 中国药物警戒, 2020, 17(9): 636-642.

LI Hui, WANG Dandan, YANG Han, ZHANG Xuenong. Research Progress on Drug-loaded Albumin Nanoparticles[J]. Chinese Journal of Pharmacovigilance, 2020, 17(9): 636-642.

参考文献

[1] Elzoghby AO, Samy WM, Elgindy NA, et al.Albumin-based nanoparticles as potential controlled release drug delivery systems[J]. J Control Release,2012,157(2):168-182.
[2] Guo X, Wei X, Chen Z, et al.Multifunctional nanoplatforms for subcellular delivery of drugs in cancer therapy[J]. Prog Mater Sci,2020,107:100599.
[3] Ruan C, Liu L, Lu Y, et al.Substance P-modified human serum albumin nanoparticles loaded with paclitaxel for targeted therapy of glioma[J]. Acta Pharm, Sin B,2018,8(1):85-96.
[4] Desale JP, Swami R, Kushwah V, et al.Chemosensitizer and docetaxel-loaded albumin nanoparticle: overcoming drug resistance and improving therapeutic efficacy[J]. Nanomedicine (Lond), 2018,13(21):2759-2776.
[5] Hyun H, Park J, Willis K, et al.Surface modification of polymer nanoparticles with native albumin for enhancing drug delivery to solid tumors[J]. Biomaterials, 2018,180:206-224.
[6] Zhang Y, Guo Z, Cao Z, et al.Endogenous albumin-mediated delivery of redox-responsive paclitaxel-loaded micelles for targeted cancer therapy[J]. Biomaterials,2018,183:243-257.
[7] Zhang Z, Yu P, Gou Y, et al.Novel Brain-Tumor-Inhibiting Copper(II) Compound Based on a Human Serum Albumin (HSA)-Cell Penetrating Peptide Conjugate[J]. J Med Chem, 2019, 62(23):10630-10644.
[8] Zhao P, Wang Y, Kang X, et al.Dual-targeting biomimetic delivery for anti-glioma activity via remodeling the tumor microenvironment and directing macrophage-mediated immunotherapy[J]. Chem Sci,2018, 9(10):2674-2689.
[9] Gawde KA, Sau S, Tatiparti K, et al.Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers[J]. Colloids Surf B Biointerfaces,2018,167:8-19.
[10] Huang D, Chen YS, Green CR, Rupenthal ID.Hyaluronic acid coated albumin nanoparticles for targeted peptide delivery in the treatment of retinal ischaemia[J]. Biomaterials,2018,168:10-23.
[11] Saleh T, Soudi T, Shojaosadati SA.Aptamer functionalized curcumin-loaded human serum albumin (HSA) nanoparticles for targeted delivery to HER-2 positive breast cancer cells[J]. Int J Biol Macromol,2019,130:109-116.
[12] Xu L, He XY, Liu BY, et al.Aptamer-functionalized albumin-based nanoparticles for targeted drug delivery[J]. Colloids Surf B Biointerfaces,2018,171:24-30.
[13] Battogtokh G, Gotov O, Kang JH, et al.Triphenylphosphine-docetaxel conjugate-incorporated albumin nanoparticles for cancer treatment[J]. Nanomedicine (Lond),2018,13(3):325-338.
[14] Saha A, Pradhan N, Chatterjee S, et al.Fatty-Amine-Conjugated Cationic Bovine Serum Albumin Nanoparticles for Target-Specific Hydrophobic Drug Delivery[J]. ACS Applied Nano Materials, 2019,2:3671-3683.
[15] Yang Z, Chen Q, Chen J, et al.Tumor-pH-Responsive Dissociable Albumin-Tamoxifen Nanocomplexes Enabling Efficient Tumor Penetration and Hypoxia Relief for Enhanced Cancer Photodynamic Therapy[J]. Small, 2018,14(49):e1803262.
[16] Saleh T, Soudi T, Shojaosadati SA.Redox responsive curcumin-loaded human serum albumin nanoparticles: Preparation, characterization and in vitro evaluation[J]. Int J Biol Macromol, 2018,114:759-766.
[17] Yang G, Phua SZF, Lim WQ, et al.A Hypoxia-Responsive Albumin-Based Nanosystem for Deep Tumor Penetration and Excellent Therapeutic Efficacy[J]. Adv Mater, 2019,31(25):e1901513.
[18] Rajendrakumar SK, Cherukula K, Park HJ, et al.Dual-stimuli-responsive albumin-polyplex nanoassembly for spatially controlled gene release in metastatic breast cancer[J]. J Control Release, 2018,276:72-83.
[19] Sun Y, Zhao Y, Teng S, et al.Folic acid receptor-targeted human serum albumin nanoparticle formulation of cabazitaxel for tumor therapy[J]. Int J Nanomedicine, 2018,14:135-148.
[20] Phuong PTT, Lee S, Lee C, et al.Beta-carotene-bound albumin nanoparticles modified with chlorin e6 for breast tumor ablation based on photodynamic therapy[J]. Colloids Surf B Biointerfaces, 2018,171:123-133.
[21] Salehiabar M, Nosrati H, Javani E, et al.Production of biological nanoparticles from bovine serum albumin as controlled release carrier for curcumin delivery[J]. Int J Biol Macromol, 2018,115:83-89.
[22] Tazhbayev Y, Mukashev O, Burkeev M, et al.Hydroxyurea-Loaded Albumin Nanoparticles: Preparation, Characterization, and In Vitro Studies[J]. Pharmaceutics,2019,11(8):410.
[23] He S, Lin Q, Qu M, et al.Liver-Targeted Co-delivery of Entecavir and Glycyrrhetinic Acid Based on Albumin Nanoparticle To nhance the Accumulation of Entecavir[J]. Mol Pharm, 2018,15(9):3953-3961.
[24] Demirkurt B, Akdogan Y.Development of an Ionic Liquid Based Method for the Preparation of Albumin Nanoparticles[J]. Chemistry Select, 2018,3:9940-9945.

载药白蛋白纳米粒的研究进展

Research Progress on Drug-loaded Albumin Nanoparticles

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[2]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[3]	辛灵怡, 杨洋, 朱婧, 何娜, 张静媚, 王航天, 陈琴华, 杨光义. 重楼抗肿瘤活性成分分类及作用机制研究进展[J]. 中国药物警戒, 2024, 21(2): 235-240.
[4]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[5]	张亮亮, 胡昌坤, 吴泽坤, 周维, 廖泽彬, 高月. 富马酸二甲酯对肠道辐射损伤防护作用及机制研究[J]. 中国药物警戒, 2024, 21(1): 83-88.
[6]	熊玮仪, 任经天. 抗肿瘤药说明书安全性信息上市后修订的考虑要点[J]. 中国药物警戒, 2024, 21(1): 94-97.
[7]	张立, 汪余嘉, 张玲玲, 陈家鑫, 林敏华, 林小惠, 聂雪坤. 真实世界免疫检查点抑制剂相关不良反应监测数据分析[J]. 中国药物警戒, 2023, 20(9): 1035-1038.
[8]	何雄, 马俊龙, 阳国平. 基于FAERS对靶向HER2抗体偶联药品不良反应/事件的分析[J]. 中国药物警戒, 2023, 20(8): 915-920.
[9]	张夏兰, 袁静, 吴斌, 秦媛媛. 甲磺酸阿帕替尼在恶性肿瘤患者的用药特征分析[J]. 中国药物警戒, 2023, 20(8): 927-932.
[10]	郑轶, 罗枭, 张朋朋, 刘永梅, 叶小飞, 郭晓晶, 陈霞, 贺佳. 基于主动监测系统的免疫检查点抑制剂心肌炎不良反应探索[J]. 中国药物警戒, 2023, 20(6): 634-638.
[11]	辛雨濛, 卢天公, 孙震晓. 甘草干姜汤对顺铂所致巨噬细胞毒性的保护作用[J]. 中国药物警戒, 2023, 20(6): 661-670.
[12]	李容容, 李盟, 苟悦, 罗琼, 吕桦, 孙鑫, 刘成海. 113例抗肿瘤药物相关肝损伤的临床特点及危险因素分析[J]. 中国药物警戒, 2023, 20(5): 505-510.
[13]	罗世书, 屈杰, 周楠, 徐翠香, 刘屹, 张丽洁, 王建华. 289例单克隆抗体抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2023, 20(4): 444-448.
[14]	胡碧原, 汪静, 郑微旗, 胡宏平, 陈泳伍. 注射用伏立康唑致自杀倾向与感觉异常1例分析[J]. 中国药物警戒, 2023, 20(4): 469-472.
[15]	杨岩, 周德喜, 吴欣俐, 薛淑雅, 丁海华, 张泉, 张云玲. 84例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2023, 20(3): 334-338.